HSV 测试市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球单纯疱疹病毒（HSV）检测市场规模达6.101亿美元，预计到2034年将以6.1%的复合年增长率成长，达到11亿美元。这一成长动能主要得益于全球单纯疱疹病毒感染病例的不断增加，以及人们对性传染感染（STI）的认识不断提高，以及对早期准确诊断的重要性的重视。临床和家用检测解决方案的需求不断增长，持续影响市场动态。多重PCR、自动化血清学平台、快速试剂盒和即时检测等诊断技术的创新，正在推动检测准确性和可及性的提高，尤其是在医疗资源匮乏的地区和高通量环境下。

广泛的性健康倡议、强化的筛检政策，以及 HSV 检测日益融入多疾病谱和电子医疗系统，都有助于提高 HSV 检测的普及率。以患者为中心、便利诊断的全面转变，也促使医疗保健产业越来越青睐快速、分散的检测模式。这些检测能够减少污名化，支持更快的临床决策，并为门诊和居家照护环境带来更多便利，从而增强其在更广泛的公共卫生策略中的价值。

HSV-1/HSV-2 联合检测在 2024 年占据最大份额，达到 52.2%，这得益于其能够在一次检测中同时检测两种类型的单纯疱疹病毒。这些涵盖分子和血清学形式的联合检测旨在简化诊断工作流程，并提高临床和公共卫生环境中的筛检准确性。它们能够识别有症状和无症状感染，从而支持做出更明智的医疗决策，尤其是在生殖健康和产前护理领域。随着高风险族群对高效诊断的需求不断增长，双标靶检测正成为性传染感染综合检测的标准。

2024年，血清学检测在各类检测中也占了最大份额，达51.6%。这些基于抗体的检测在检测既往HSV感染情况方面备受​​推崇，尤其适用于无明显症状的患者。其应用范围涵盖大规模筛检计画、产前护理和常规性传染感染诊断。由于血清学检测相容于高容量实验室操作，因此能够实现资料自动输出、高效的批量检测，并与集中式诊断系统无缝整合。血清学检测的可扩展性和成本效益使其成为全球医院、实验室和公共卫生计画的重要工具。

2024年，美国单纯疱疹病毒（HSV）检测市场规模达2.472亿美元，巩固了其在全球单纯疱疹病毒检测领域的重要地位。由于单纯疱疹病毒感染在成年人口中普遍存在，对可靠诊断方法的需求仍然强劲。口腔疱疹（通常在儿童早期感染）和生殖器疱疹（一种常见的性传染感染）都导致了美国检测量居高不下。完善的医疗基础设施、积极的疾病宣传工作以及持续的研究投入，进一步巩固了美国的市场地位。

引领全球 HSV 检测市场的知名公司包括雅培实验室 (Abbott Laboratories)、TRUPCR、Quest Diagnostics、McKesson Medical-Surgical、Bio-Rad Laboratories、赛默飞世尔科技 (Thermo Fisher Scientific)、CTK Biotech、QuidelOrio​​er Corporation、Incoopi​​台、Yumo Fisher Scientic、Pic​​Ya Biotecha​​a、Saku​​Ykia. Bioscience、PrivaPath Diagnostics、F. Hoffmann-La Roche 和 Becton, Dickinson and Company。参与 HSV 检测市场的公司正透过专注于技术创新、产品组合扩展和全球推广来提升其地位。一项主要策略包括开发支援分散和早期检测的快速、即时和组合诊断测试。公司正在投资自动化以及诊断工具与电子健康平台的集成，以提高资料管理和工作流程效率。与医疗保健提供者、公共卫生机构和分销商的合作有助于扩大覆盖范围，尤其是在服务不足的市场。准确性、可负担性和易用性的不断改进确保产品满足日益增长的公共卫生需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • HSV感染盛行率上升
    • 分子诊断技术的持续进步
    • 政府对性传染感染监测和预防计画的措施和资金
  • 产业陷阱与挑战
    • 监管和报销挑战
    • 社会耻辱和隐私问题
  • 市场机会
    • 持续改进家用和自测试剂盒
• 成长潜力分析
• 监管格局
• 技术进步
  • 当前的技术趋势
  • 新兴技术
• 供应链分析
• 报销场景
• 2024年定价分析
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 北美洲
  • 欧洲
  • 亚太地区
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係和合作
  • 新产品发布
  • 扩张计划

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 仪器
• 试剂和试剂盒

第六章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• HSV-1/HSV-2 结合
• 单纯疱疹病毒-1
• 单纯疱疹病毒-2

第七章：市场估计与预测：按测试类型，2021 - 2034 年

• 主要趋势
• 血清学检测
• 直接检测试验
  • 聚合酶连锁反应
  • 病毒培养
• 即时检验

第八章：市场估计与预测：按样本类型，2021 - 2034 年

• 主要趋势
• 血
• 拭子
• 脑脊髓液
• 尿

第九章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 诊断实验室
• 居家护理/自我检测
• 其他最终用途

第十章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋

第 11 章：公司简介

• Abbott Laboratories
• AdvaCare Pharma
• Becton, Dickinson and Company
• Bio-Rad Laboratories
• bioWORLD
• CTK Biotech
• DiaSorin
• F. Hoffmann-La Roche
• Hologic
• Innermost Healthcare
• McKesson Medical-Surgical
• Meridian Bioscience
• PrivaPath Diagnostics
• Quest Diagnostics
• QuidelOrtho Corporation
• Thermo Fisher Scientific
• TRUPCR
• ZEUS Scientific

The Global HSV Testing Market was valued at USD 610.1 million in 2024 and is estimated to grow at a CAGR of 6.1% to reach USD 1.1 billion by 2034. This upward trajectory is largely fueled by the increasing global prevalence of herpes simplex virus infections, along with heightened awareness surrounding sexually transmitted infections (STIs) and the critical importance of early and accurate diagnosis. Rising demand for both clinical and at-home testing solutions continues to shape market dynamics. Innovations in diagnostic technologies-such as multiplex PCR, automated serological platforms, rapid kits, and point-of-care testing-are driving improved accuracy and accessibility, particularly in underserved regions and high-throughput settings.

Widespread sexual health initiatives, enhanced screening policies, and the growing integration of HSV testing into multi-disease panels and electronic health systems are contributing to stronger adoption. The overall shift toward patient-centered, accessible diagnostics is also prompting the healthcare sector to increasingly prefer rapid, decentralized testing formats. These tests reduce stigma, support quicker clinical decisions, and offer more convenience in outpatient and home-care environments, reinforcing their value in broader public health strategies.

The HSV-1/HSV-2 combined testing segment held the largest share in 2024 at 52.2%, driven by its ability to detect both types of herpes simplex virus in a single test. These combination assays, covering both molecular and serological formats, are designed to streamline diagnostic workflows and enhance screening accuracy across clinical and public health environments. Their capacity to identify both symptomatic and asymptomatic infections supports better-informed medical decisions, particularly in reproductive health and prenatal care contexts. As demand rises for efficient diagnosis in high-risk groups, dual-target assays are becoming standard in comprehensive STI panels.

Serological tests also captured the largest share of 51.6% within the testing type category in 2024. These antibody-based tests are highly valued for detecting prior HSV exposure, especially in patients with no visible symptoms. Their use spans large-scale screening programs, prenatal care, and general STI diagnostics. Thanks to their compatibility with high-volume laboratory operations, serological tests offer automated data output, efficient batch testing, and smooth integration with centralized diagnostics. Their scalability and cost-effectiveness make them essential tools in hospitals, labs, and public health programs worldwide.

United States HSV Testing Market generated USD 247.2 million in 2024, cementing its role as a key contributor to the global HSV testing landscape. With HSV infections widespread across the adult population, the need for reliable diagnostics remains strong. Oral herpes, often contracted early in life, and genital herpes, a common STI, both contribute to high national testing volumes. Supportive healthcare infrastructure, active disease awareness efforts, and continued research investment further strengthen the country's market position.

Notable companies leading the Global HSV Testing Market include Abbott Laboratories, TRUPCR, Quest Diagnostics, McKesson Medical-Surgical, Bio-Rad Laboratories, Thermo Fisher Scientific, CTK Biotech, QuidelOrtho Corporation, Innermost Healthcare, DiaSorin, Hologic, AdvaCare Pharma, ZEUS Scientific, bioWORLD, Meridian Bioscience, PrivaPath Diagnostics, F. Hoffmann-La Roche, and Becton, Dickinson and Company. Companies competing in the HSV testing market are advancing their positions by focusing on technological innovation, portfolio expansion, and global outreach. A major strategy includes the development of rapid, point-of-care, and combination diagnostic tests that support decentralized and early detection. Firms are investing in automation and integration of diagnostic tools with electronic health platforms to improve data management and workflow efficiency. Partnerships with healthcare providers, public health agencies, and distributors help in expanding reach, especially in underserved markets. Continuous improvements in accuracy, affordability, and ease of use ensure that products meet growing public health demands.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Type trends
  • 2.2.4 Test type trends
  • 2.2.5 Sample type trends
  • 2.2.6 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of HSV infections
    • 3.2.1.2 Ongoing advancements in molecular diagnostic technologies
    • 3.2.1.3 Government initiatives and funding for STI surveillance and prevention programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory and reimbursement challenges
    • 3.2.2.2 Social stigma and privacy concerns
  • 3.2.3 Market opportunities
    • 3.2.3.1 Ongoing enhancement in home-based and self-testing kits
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Supply chain analysis
• 3.7 Reimbursement scenario
• 3.8 Pricing analysis, 2024
• 3.9 Future market trends
• 3.10 Gap analysis
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Reagents and kits

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 HSV-1/HSV-2 Combines
• 6.3 HSV-1
• 6.4 HSV-2

Chapter 7 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Serological tests
• 7.3 Direct detection tests
  • 7.3.1 PCR
  • 7.3.2 Viral culture
• 7.4 Point-of-care tests

Chapter 8 Market Estimates and Forecast, By Sample Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Blood
• 8.3 Swabs
• 8.4 Cerebrospinal fluid
• 8.5 Urine

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Diagnostic laboratories
• 9.4 Home care/self-testing
• 9.5 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 AdvaCare Pharma
• 11.3 Becton, Dickinson and Company
• 11.4 Bio-Rad Laboratories
• 11.5 bioWORLD
• 11.6 CTK Biotech
• 11.7 DiaSorin
• 11.8 F. Hoffmann-La Roche
• 11.9 Hologic
• 11.10 Innermost Healthcare
• 11.11 McKesson Medical-Surgical
• 11.12 Meridian Bioscience
• 11.13 PrivaPath Diagnostics
• 11.14 Quest Diagnostics
• 11.15 QuidelOrtho Corporation
• 11.16 Thermo Fisher Scientific
• 11.17 TRUPCR
• 11.18 ZEUS Scientific